GB2081092A - Improving taste acceptability of pharmaceutical compositions - Google Patents

Improving taste acceptability of pharmaceutical compositions Download PDF

Info

Publication number
GB2081092A
GB2081092A GB8121487A GB8121487A GB2081092A GB 2081092 A GB2081092 A GB 2081092A GB 8121487 A GB8121487 A GB 8121487A GB 8121487 A GB8121487 A GB 8121487A GB 2081092 A GB2081092 A GB 2081092A
Authority
GB
United Kingdom
Prior art keywords
water
medicinal
objectionable
molecular weight
high molecular
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
GB8121487A
Other versions
GB2081092B (en
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Yamanouchi Pharmaceutical Co Ltd
Original Assignee
Yamanouchi Pharmaceutical Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Yamanouchi Pharmaceutical Co Ltd filed Critical Yamanouchi Pharmaceutical Co Ltd
Publication of GB2081092A publication Critical patent/GB2081092A/en
Application granted granted Critical
Publication of GB2081092B publication Critical patent/GB2081092B/en
Expired legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1652—Polysaccharides, e.g. alginate, cellulose derivatives; Cyclodextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1617—Organic compounds, e.g. phospholipids, fats
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1635—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Biophysics (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Molecular Biology (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

A medicinal composition which masks the objectionable taste of a water-soluble medicinal component thereof, comprises said objectionable-tasting water-soluble medicinal component, waxy material, and water swellable high molecular weight material. Suitable water-swellable materials include hydroxypropyl cellulose, carboxymethyl cellulose, carboxymethyl cellulose calcium salt, crosslinked polyvinyl-pyrrolidone, and pharmaceutically acceptable ion-exchange resins. Medicinal components include the hydrochloride salts of talampicillin, indenolol, hydralazine, and chlorpromazine. The imposition is prepared by dispersing the other materials in the molten waxy material and solidifying, followed by grinding if necessary.

Description

SPECIFICATION Medicinal composition This invention relates to medicinal compositions containing water-soluble distasteful medicinal substances and to their production.
Bitter medicinal substances are usually administered in a form in which the bitterness is masked, e.g. as sugar-coated tablets, film-coated tablets, capsules, etc. However, there is a keen demand for such masked bitter medicinal substances in a convenient form for preparation, such as powder, fine granules, granules etc., and various attempts have been made to mask the bitterness of medicinal substances in such forms.In one such attempt a powder is produced by melting a waxy solid material having a melting point of about 40-100"C, dispersing the bitter medicinal substances in the molten material, and then (a) cooling and solidifying the dispersion by spraying it through a nozzle or (b) solidifying the dispersion by cooling followed by crushing; however on oral administration of a conventional composition so prepared, the medicinal substance is reluctant to dissolve in the mouth so that whilst the composition may mask the bitterness well it gives poor dissolution of the medicinal substance in the alimentary canal and hence reduces the bioavailability of the medicinal substance. For example, U.K.
Pat. No. 1,323,161 discloses a method in which particles of a bitter medicinal substance are coated with a mixture (having a melting point higher than 95"C) of more than 50% hardened castor oil and less than 50% fatty acid having more than 16 carbon atoms; the medical composition obtained may mask the bitterness well but gives poor absorptivity of the medicinal substance.
To overcome this difficulty, it has been considered to compound the waxy solid material with a watersoluble material having a melting point of 40-1 OO"C (e.g. polyethylene glycol, a sucrose fatty acid ester having high HLB, etc.,) but such water-suluble material does not uniformly mix with the waxy solid material even if they are mixed molten. Furthermore, compounding with a water-soluble excipient such as lactose, mannitol, etc., is scarcely effective for improvement of fault described above.
According to this invention, there is provided a medicinal composition which masks the objectionable taste of a water-soluble medicinal component thereof, the composition comprising said objectionable-tasting water-soluble medicinal component, waxy material, and water-swellable high molecular weight material.
There is also provided a method of producing such a composition which comprises dispersing a watersoluble medicinal substance of objectionable taste in molten waxy material together with water-swellable high molecular weight material and then solidifying the dispersion.
One or more waxing materials and one or more water-swellable high molecular weight materials may be used.
The medicinal substances used in the composition of this invention are those soluble in water and having objectionable taste, e.g. severe bitterness, but these is no particular restriction on the kind and range of them. Practical examples of them are talampicilline hydrochloride which is an antibiotic, indenolol hydrochloride which is a blocker, hydralazine hydrochloride which is an antidepressant, chloropromazine hydrochloride which is a transquilizer, etc.
Examples of the waxy materials used in this invention are waxes such as carbauba wax, beeswax, etc.; solid fats and oils such as castor wax, acetoglyceride, etc.; higher fatty acids such as stearic acid, palmitic acid, etc.; and high alcohols such as cetyl alcohol, stearyl alcohol, etc.
Examples of water-swellable high molecular weight materials used in this invention are hydroxypropyl cellulose of a low substitution degree (L HPC), carboxymethyl cellulose or a calcium salt thereof, crosslinked polyvinyl pyrrolodone (PVPP), ion-exchange resins used for medicaments, etc.
In the method according to the invention the molten dispersion may for example be solidified by cooling by spraying through a nozzle or be solidified by cooling en masse and then ground into fine granules.
The proportion of waxy material is suitably more than 3 parts (by weight) to one part of the medicinal component and that of the water-swellable high molecular weight material is suitably 0.05-0.3 part to one part of the waxy material. If the compounding ratio of the waxy material is less, the viscosity of the dispersion obtained by dispersing the medicinal component and the high molecular weight material in the molten waxy material becomes high, which makes it difficult to obtain fine granules or particles by spraying the dispersion and hence to obtain well coated granules or particles. If the compounding ratio of the high molecular weight material is less, the swelling power and the dissolving effect become insufficient, while if the compounding ratio is too high, the viscosity of the dispersion becomes high and hence it becomes difficult to make fine granules or particles.
Various preparations may be produced using the composition of this invention by adding thereto conventional preparative excipient such as lactose, mannitol, etc., and, if necessary, other ingredients such as coloring agents, odorants, etc., or these preparations may be produced by adding the aforesaid components during the production of the composition.
To exhibit the effects of the compositions of this invention, organoleptic test results on bitterness and dissolution test results are shown in Table 1 together with comparison sample results.
Table 1
Test sample Dissolution test result (%) Example Medicinal Waxy High Weight Organoleptic 30 min. 60 min. 90 mm.- substance material molecular ratio test result material Contrast1 Talampici- Lubriwax - 1:4 (-) 11.6 12.1 13.5 iline hydro chloride 1 " " L-HPC 1:3::0.25 (-) 82.9 85.4 88.1 2 " " L-HPC 1:4:0.5 (-) 92.1 96.4 96.8 3 ,, " CMC Ca 1:4:0.5 (-) 91.5 96.3 97.2 4 ,, " Amberite 1:4:0.5 (-) 89.4 93.8 94.3 5 ,, ,, PVPP 1:5:1 (-) 96.3 98.5 98.2 6 " Himako L-HPC 1:5::1 (-) 90.3 93.4 94.1 Contrast 2 Hydralazine hydrochloride Lubriwax - 1:5 (-) 5.2 6.9 7.9 7 " " L-HPC 1:5:1 (-) 83.9 85.4 87.1 8 CMCCa 1:5:1 (-) 81.8 84.5 87.7 Contrast3 Indenolo ,, - 1:5 (-) 11.6 15.7 17.3 hydrochloride 9 " " L-HPC 1:5::1 (-) 85.2 87.2 89.3 Contrast4 Chloropromazine " " 1:5 (-) 35.0 36.7 34.8 hydrochloride 10 " " L-HPC 1:5:1 (-) 87.9 95.5 96.6 Note: (1) In the organoleptic test, (-) means that no bit terness was tasted.
(2) The measurement of dissolution was per formed by adding 100 mg of the fine granules of the sample to a 100 milliliter bottle contain ing 50 ml of the Japan Pharmacopoeia 1st liquid of 37 + 0.5 C, shaking the bottle in a constant-temperature bath at an amplitude of 3.5 cm and a frequency of 120 per minute, and then measuring the medicinal substance thus dissolved by absorptiometry.
(3) Comparison (contrast) samples 1,2,3 and 4 were produced by following the method as in Example 1.
The results shown in the above table indicate that the compositions of this invention gave no bitterness in the organoleptic test and at the same time showed excellent dissolution in comparison with the contrast compositions.
The compositions of this invention and their production are further explained by the following Examples.
Example 1 In 300 g of a hydrogenated vegetable oil (Lubriwax 102H, a trade name, made by Freund Industries Co., Ltd.) melted on an oil bath were uniformly dispersed 100 g of talampicilline hydrochloride and 25 g of L-hydroxyporpyl cellulose (L-HPC, a trade name, made by Shin-Etsu Chemical Co., Ltd.) and then the dispersion was sprayed in a room at temperatures below 30 C by means of a rotary disc type atomizer (made by Iwai Kikai Kogyo K. K.) to provide coated granules of 32-80 mesh.
Example 2 Talampicilline hydrochloride 100 g Hydrogenated vegetable oil (Lubriwax 102H 400g L-Hydroxypropyl cellulose (L-HPC) 50 g Coated granules were produced using the above components in the same manner as in Example 1 Example 3 Talampicilline hydrochloride 100 g Hydrogenated vegetable oil (Lubriwax 102H) 400g Carboxymethyl cellulose calcium (ECG 505, a trade name, made by Gotoku Yakuhin Kogyo K. K.) 50 g Coated granules were produced using the above components in the same manner as in Example 1.
Example 4 Talampicilline hydrochloride 100 g Hydrogenated vegetable oil (Lubriwax 102H) 400g lon exchange resin (Amberite IRP-88, a trade name, made by Rhom and Haas Co.) 50 gs/ Coated granules were produced using the above components in the same manner as in Example 1.
Example 5 Talampicilline hydrochloride 100 g Hydrogenated vegetable oil (Lubriwax 102H) 500 g Crosslinked polyvinylpyrrolidone (Kollidon CL, a trade name, made by BASF A.G.) 100g Coated granules were produced using the above components in the same manner as in Example 1.
Example 6 Talampicilline hydrochloride 100 g Hydrogenated vegetable oil (Himi Ko, a trade name, made by Kawaken Fine Chemical Co., Ltd.) 100g Coated granules were produced using the above components in the same manner as in Example 1.
Example 7 Hydralazine hydrochloride 100 g Hydrogenated vegetable oil (Lubriwax 102H) L-Hydroxypropyl cellulose (L-HPC) 100 g Coated granules were produced using the above components in the same manner as in Example 1.
Example 8 Hydaralazine hydrochloride 100 g Hydrogenated vegetable oil (Lubriwax 102H) Carboxymethyl cellulose calcium (ECG5O5) 100 g Coated granules were produced using the above components in the same manners in Example 1.
Example 9 Indenolol hydrochloride 100 9 Hydrogenated vegetable oil (Lubriwax 102H 500 g L-Hydroxypropyl cellulose (L-HPC) 100 g Example 10 Chloropromazine hydrochloride 100 g Hydrogenated vegetable oil (Lubriwax 102H) 500 g L-Hydroxypropyl cellulose (L-HPC) 100 g Coated granules were produced using the above components in the same manner as in Example 1.

Claims (11)

1. A medicinal composition which masks the objectionable taste of a water-soluble medicinal component thereof, the composition comprising said objectionable-tasting water-soluble medicinal component, waxy material, and water-swellable high molecular weight material.
2. A composition according to claim 1 wherein the proportion of waxy material is over 3 parts by weight to one part of objectionable-testing watersoluble medicinal component, and the proportion of water-swellable high molecular weight material is 0.05-0.3 part by weight to one part of waxy material.
3. A composition according to claim 1 or 2 wherein the waxy material is at least one material selected from waxes, solid fats and oils, higher fatty acids, and higher alcohols, and the water-swellable high molecular weight material is at least one of hydroxypropyl cellulose of low substitution degree, carboxymethyl cellulose, carboxymethyl cellulose calcium salt, crosslinked polyvinylpyrrolidone, and medical ion-exchange resins.
4. A composition according to claim 1, 2 or 3, wherein the objectionable-tasting water-soluble medicinal component comprises talampicilline hydrochloride, indenolol hydrochloride, hydralazine hydrochloride, or chloropromazine hydrochloride.
5. A composition according to any preceding claim wherein the water-swellable high molecular weight material comprises hydroxypropyl cellulose of low substitution degree.
6. A method of producing a composition according to claim 1 which comprises dispersing a watersoluble medicinal substance of objectionable-taste in molten waxy material together with waterswellable high molecular weight material and then solidifying the dispersion.
7. A method according to claim 6 wherein the molten dispersion is solidified by spray cooling.
8. A method according to claim 6 wherein the molten dispersion is solidified by cooling and then ground.
9. Acomposition produced by the method according to claim 6,7 or 8.
10. A medicinal composition substantially as hereinbefore described in any one of Examples 1 to 10.
11. A medicinal preparation comprising a composition according to any of claims 1 to 5 and 10 in an excipient.
GB8121487A 1980-07-11 1981-07-13 Improving taste acceptability of pharmaceutical compositions Expired GB2081092B (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
JP55094780A JPS6029682B2 (en) 1980-07-11 1980-07-11 Bitter-free pharmaceutical composition and method for producing the same

Publications (2)

Publication Number Publication Date
GB2081092A true GB2081092A (en) 1982-02-17
GB2081092B GB2081092B (en) 1985-01-23

Family

ID=14119597

Family Applications (1)

Application Number Title Priority Date Filing Date
GB8121487A Expired GB2081092B (en) 1980-07-11 1981-07-13 Improving taste acceptability of pharmaceutical compositions

Country Status (4)

Country Link
JP (1) JPS6029682B2 (en)
DE (1) DE3126258A1 (en)
FR (1) FR2486398A1 (en)
GB (1) GB2081092B (en)

Cited By (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB2153678A (en) * 1984-02-08 1985-08-29 Erba Farmitalia Pharmaceutical composition
US4778676A (en) * 1985-12-20 1988-10-18 Warner-Lambert Company Confectionery delivery system for actives
GB2204792A (en) * 1987-05-14 1988-11-23 Glaxo Group Ltd Cefuroxime axetil compositions
US4874613A (en) * 1987-03-06 1989-10-17 Baker Cummins Pharmaceuticals, Inc. Taste concealing pharmaceutical dosage unit
US5057319A (en) * 1987-12-23 1991-10-15 Smith Kline Dauelsberg Gmbh Pharmaceutical compositions of cimetidine
EP0587744A1 (en) * 1991-05-28 1994-03-23 McNEIL-PPC, Inc. Chewable drug-delivery composition
WO1994020075A1 (en) * 1993-03-08 1994-09-15 Laboratoires Virbac Controlled release microcapsules, process for their preparation and pharmaceutical or veterinary compositions containing same
US5380535A (en) * 1991-05-28 1995-01-10 Geyer; Robert P. Chewable drug-delivery compositions and methods for preparing the same
EP0670716A1 (en) * 1992-11-30 1995-09-13 Kv Pharmaceutical Company Tastemasked pharmaceutical materials
BE1009257A3 (en) * 1995-03-21 1997-01-07 Universiteit Gent Lab Voor Far Pharmaceutical matrix.
WO1997033621A1 (en) * 1996-03-12 1997-09-18 F.H. Faulding & Co. Limited Pharmaceutical compositions
US6368635B1 (en) 1991-04-19 2002-04-09 Takeda Chemical Industries, Ltd. Gastrointestinal mucosa-adherent matrixes pharmaceutical preparations and a coating composition
US7727548B2 (en) 2000-03-01 2010-06-01 Eisai R&D Management Co., Ltd. Rapidly disintegrable tablet containing polyvinyl alcohol
WO2011128906A1 (en) 2010-04-12 2011-10-20 S. Zhaveri Pharmakem Pvt. Ltd. Ciprofloxacin dry syrup composition
CN103877027A (en) * 2014-03-17 2014-06-25 广东药学院 Cefuroxime axetil hot-melt coating composition and preparation method of composition

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS58216118A (en) * 1982-06-11 1983-12-15 Morishita Seiyaku Kk Amino acid pharmaceutical preparation composition and its preparation
JPH0761962B2 (en) * 1986-05-01 1995-07-05 富山化学工業株式会社 Method for producing coated fine granules
JP4570725B2 (en) * 2000-04-05 2010-10-27 大塚製薬株式会社 Composition for pharmaceutical preparation

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB1550359A (en) * 1975-08-07 1979-08-15 Beecham Group Ltd Antibiotic compositions for oral administration
JPS5231981A (en) * 1975-08-18 1977-03-10 Takeda Chem Ind Ltd Microcapsule preparation method
JPS52120976A (en) * 1976-04-06 1977-10-11 Fuji Photo Film Co Ltd Manufacture of capsule having wall of waxy material

Cited By (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB2153678A (en) * 1984-02-08 1985-08-29 Erba Farmitalia Pharmaceutical composition
US4778676A (en) * 1985-12-20 1988-10-18 Warner-Lambert Company Confectionery delivery system for actives
US4874613A (en) * 1987-03-06 1989-10-17 Baker Cummins Pharmaceuticals, Inc. Taste concealing pharmaceutical dosage unit
GB2204792A (en) * 1987-05-14 1988-11-23 Glaxo Group Ltd Cefuroxime axetil compositions
GB2204792B (en) * 1987-05-14 1991-01-23 Glaxo Group Ltd Pharmaceutical composition
US5057319A (en) * 1987-12-23 1991-10-15 Smith Kline Dauelsberg Gmbh Pharmaceutical compositions of cimetidine
US6368635B1 (en) 1991-04-19 2002-04-09 Takeda Chemical Industries, Ltd. Gastrointestinal mucosa-adherent matrixes pharmaceutical preparations and a coating composition
EP0587744A4 (en) * 1991-05-28 1994-05-25 Affinity Biotech Inc Chewable drug-delivery composition
US5320848A (en) * 1991-05-28 1994-06-14 Affinity Biotech, Inc. Chewable drug-delivery composition
EP0587744A1 (en) * 1991-05-28 1994-03-23 McNEIL-PPC, Inc. Chewable drug-delivery composition
US5380535A (en) * 1991-05-28 1995-01-10 Geyer; Robert P. Chewable drug-delivery compositions and methods for preparing the same
EP0670716A4 (en) * 1992-11-30 1996-10-02 Kv Pharm Co Tastemasked pharmaceutical materials.
EP0670716A1 (en) * 1992-11-30 1995-09-13 Kv Pharmaceutical Company Tastemasked pharmaceutical materials
FR2702375A1 (en) * 1993-03-08 1994-09-16 Virbac Laboratoires Progressive release microcapsules, process for their preparation and pharmaceutical or veterinary compositions containing them
WO1994020075A1 (en) * 1993-03-08 1994-09-15 Laboratoires Virbac Controlled release microcapsules, process for their preparation and pharmaceutical or veterinary compositions containing same
BE1009257A3 (en) * 1995-03-21 1997-01-07 Universiteit Gent Lab Voor Far Pharmaceutical matrix.
US6132769A (en) * 1995-03-21 2000-10-17 Universiteit Gent Pharmaceutical matrix pellets, tablets and composition for the preparation thereof
WO1997033621A1 (en) * 1996-03-12 1997-09-18 F.H. Faulding & Co. Limited Pharmaceutical compositions
US7727548B2 (en) 2000-03-01 2010-06-01 Eisai R&D Management Co., Ltd. Rapidly disintegrable tablet containing polyvinyl alcohol
US8263123B2 (en) 2000-03-01 2012-09-11 Eisai R&D Management Co., Ltd. Rapidly disintegrating tablet containing polyvinyl alcohol
WO2011128906A1 (en) 2010-04-12 2011-10-20 S. Zhaveri Pharmakem Pvt. Ltd. Ciprofloxacin dry syrup composition
CN103877027A (en) * 2014-03-17 2014-06-25 广东药学院 Cefuroxime axetil hot-melt coating composition and preparation method of composition
CN103877027B (en) * 2014-03-17 2016-01-27 广东药学院 A kind of CEFUROXIME AXETIL hot melt coated composition and preparation method thereof

Also Published As

Publication number Publication date
DE3126258A1 (en) 1982-08-05
JPS6029682B2 (en) 1985-07-12
GB2081092B (en) 1985-01-23
FR2486398A1 (en) 1982-01-15
FR2486398B1 (en) 1983-12-09
JPS5721314A (en) 1982-02-04

Similar Documents

Publication Publication Date Title
GB2081092A (en) Improving taste acceptability of pharmaceutical compositions
JP3778948B2 (en) Controlled release tablets containing water soluble drugs
AU2007352608B2 (en) Novel pharmaceutical composition
EP0670716B1 (en) Tastemasked pharmaceutical materials
US4421736A (en) Sustained release diethylpropion compositions
JP3667778B2 (en) Spheroid preparation
IE59106B1 (en) A therapeutic effervescent composition and a method of preparing the same
HU221683B1 (en) Controlled release morphine preparation
HU206265B (en) Process for producing pharmaceutical compositions comprising morphine
KR100943347B1 (en) Medicinal composition
EP1334732B1 (en) Pharmaceutical preparation of n-[2-(1,6,7,8-tetrahydro-2h-indeno[5,4 b]furan-8-yl)ethyl]propionamide coated with a copolyvidone-containing coating free of polyethylene glycol
GB1594102A (en) Ingestible coating compositions
JPH0296516A (en) Granule and production thereof
CA2325636A1 (en) Oral medicinal forms with reproducible release of the active ingr edient gatifloxacin or its pharmaceutically acceptable salts or hydrates
JPH02288821A (en) Particle and medicine preparation coated with film containing agonist
EP0855183A2 (en) Manufacture of taste-masked preparations of antibacterial quinolone derivatives
WO1997018798A1 (en) Prompt-release pharmaceutical compositions
HU204193B (en) Process for producing gemfibrosil compositions dispersible in water
EP0299668A1 (en) Pharmaceutical composition containing ibuprofen
TWI286072B (en) Sleeping medicine formed by coating solid
HU189148B (en) Process for producing pharmaceutical retarde compositions containing hardly water-soluble active agents
DE4216756A1 (en) 2-Arylpropionic acid preparations and process for their preparation
JP2004277431A (en) Granular preparation and method of producing the same
EP0557064B1 (en) Modified release formulation
JPH08325142A (en) Isopropamide iodide-containing formulation

Legal Events

Date Code Title Description
PCNP Patent ceased through non-payment of renewal fee